Illustrative image.
Hemlibra
Emicizumab
$3625.00
30mg/1ml · 1 vial
BrandBranded medicine· By Roche
Strength
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Ships cold, in insulated packing
This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
30mg/1ml
60mg/0.4ml
105mg/0.7ml
150mg/1ml
FDA boxed warningThrombotic microangiopathy and thromboembolism
Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.
Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.
About Hemlibra
Overview
Hemlibra (emicizumab) is an antibody medicine supplied in single-dose vials for injection under the skin. It is used to prevent or reduce bleeding episodes in adults and children, including newborns, with hemophilia A, with or without factor VIII inhibitors. It works by bringing together two blood-clotting proteins to take over the role of missing activated factor VIII, helping blood to clot.
What it treats
Routine prevention or reduction of bleeding episodes in adults and children, including newborns, with hemophilia A (congenital factor VIII deficiency), with or without factor VIII inhibitors.
Safety information
Side effects
Common side effects include injection-site reactions, headache and joint pain. Serious side effects include thrombotic microangiopathy (damage and blood clots in small blood vessels) and thromboembolism (blood clots that block blood vessels), associated with Hemlibra used with activated prothrombin complex concentrate (aPCC). Contact a doctor immediately if a blood clot is suspected. Antibodies against emicizumab can develop and may reduce its effectiveness. Contact your doctor promptly if Hemlibra seems to be working less well. Hemlibra can interfere with certain blood-clotting tests and make their results unreliable. Tell the healthcare professional arranging these tests that you use Hemlibra.
FDA boxed warning
Thrombotic microangiopathy and thromboembolism
Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.
Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
The FDA label lists no contraindications for Hemlibra. Some patients develop antibodies against emicizumab, including antibodies that can reduce its effect. If there are signs that treatment is becoming less effective, the prescriber should promptly assess the cause and consider changing treatment if neutralizing antibodies are suspected. Hemlibra interferes with certain blood-clotting tests, including activated clotting time (ACT), activated partial thromboplastin time (aPTT), and tests based on aPTT. These include some tests for clotting factors and factor VIII inhibitors. Intrinsic pathway clotting-based laboratory tests should not be used. Tell the healthcare team that you use Hemlibra before having clotting tests.
Using Hemlibra
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label HEMLIBRA (EMICIZUMAB) INJECTION, SOLUTION [GENENTECH, INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
NovoEight
Antihemophilic Factor (recombinant)
By Novo Nordisk
Pack · from 1 per pack
Also for blood disorders
Brand $1,034.00
Koāte‑DVI
Antihemophilic Factor (human) (factor Viii)
By Grifols
Vial · from 1 per pack
Also for blood disorders
Brand $1,034.00
RhoGAM
Anti‑d (rh₀) Immunoglobulin (human)
By Kamada
Vial · from 1 per pack
Also for blood disorders
Brand $150.00
Ferriprox
Deferiprone
By None
Tablets · from 100 per pack
Also for blood disorders
Brand $377.00